6M
LGND icon

6 Meridian’s Ligand Pharmaceuticals LGND Stock Holding History

6 Meridian’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,757
Closed -$873K – 476
2018
Q2 		$873K Sell
6,757
-67
-1% -$7.48K 0.09% 124
2018
Q1 		$703K Buy
+6,824
New +$675K 0.08% 130

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

6 Meridian's LGND Position: Q3 2018 in Review

6 Meridian sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 6,757 shares — an estimated $873K sold.

6 Meridian first reported a position in LGND in Q1 2018 and held it in 2 quarters. The position peaked at $873K in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

  • 6 Meridian reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • 6 Meridian sold 6,757 Ligand Pharmaceuticals shares in Q3 2018, an estimated $873K.
  • 6 Meridian first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • 6 Meridian's Ligand Pharmaceuticals position peaked at $873K in Q2 2018.
  • 385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on 6 Meridian's 13F filing for Q3 2018, filed 14 Nov 2018.